ALXO News and Press, ALX Oncology Holdings Inc. From 10/03/23

-- Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors -- Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for control treatment -- Company to host ...

2023-10-03 05:33:37 ET Related stories ALX Oncology Holdings: Gilead News Creates A New Risk Sibanye: Restructuring Kloof, PGM Tailings Synergies A Possibility Sibanye Stillwater: Stock Still A Buy Despite Disappointing H123 Results Sibanye Stillwater conside...

2023-10-02 17:43:39 ET Summary ALX Oncology Holdings is developing evorpacept, an engineered protein that targets CD47, a molecule associated with cancer. The company is conducting phase 2 trials for evorpacept in head and neck and gastric/GEJ cancer, but results have not been rel...

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the hosting of an...

2023-09-20 08:30:53 ET NetworkNewsWire Editorial Coverage New York, NY – September 20, 2023 – More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

2023-09-06 08:30:42 ET More on ALX Oncology Seeking Alpha’s Quant Rating on ALX Oncology Historical earnings data for ALX Oncology Financial information for ALX Oncology For further details see: ALX Oncology names new CEO as founder becomes science...

Jason Lettmann appointed as Chief Executive Officer Dr. Jaume Pons transitions to Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an i...

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two u...

2023-08-11 04:14:23 ET ALX Oncology press release ( NASDAQ: ALXO ): Q2 GAAP EPS of -$0.84 beats by $0.07 . Cash, cash equivalents and investments as of June 30, 2023, were $224.5 million. ALX Oncology believes its cash, cash equivalents, and investments along with the ...

Advancing Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423 Terminating azacitidine combination development programs: ASPEN-02 in MDS and ASPEN-05 in AML Continuing focus on combinations with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 ...